Nuvation Bio Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
NUVB$4.16-0.7%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of New York, State of New York, on this 14th day of May, 2024.
| NUVATION BIO INC. | |
| Date: May 14, 2024 | /s/ David Hung, M.D. |
|---|---|
| David Hung, M.D. | |
| Founder, President and Chief Executive Officer | |
| Date: May 14, 2024 | /s/ Moses Makunje |
| Moses Makunje, VP, Finance Principal Financial and Accounting Officer |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.